Randomized controlled trial of a MUFA or fiber-rich diet on hepatic fat in prediabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 102, Issue 5, 2017, Pages 1765-1774

  Errazuriz, Isabel ^a   Dube, Simmi ^a   Slama, Michael ^a   Visentin, Roberto ^b   Nayar, Sunita ^a   O'Connor, Helen ^a   Cobelli, Claudio ^b   Das, Swapan Kumar ^c   Basu, Ananda ^a   Kremers, Walter Karl ^a   Port, John ^a   Basu, Rita ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINOLEIC ACID; MONOUNSATURATED FATTY ACID; OLIVE OIL; PALMITIC ACID; PALMITOLEIC ACID; TRANSCRIPTION FACTOR 7 LIKE 2; TRIACYLGLYCEROL; ADIPONUTRIN, HUMAN; DEUTERIUM; FAT INTAKE; GCKR PROTEIN, HUMAN; LECTIN; MEMBRANE PROTEIN; NCAN PROTEIN, HUMAN; NERVE PROTEIN; PROTEOCHONDROITIN SULFATE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SREBF1 PROTEIN, HUMAN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TCF7L2 PROTEIN, HUMAN; TRIACYLGLYCEROL LIPASE;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY WEIGHT MAINTENANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY FIBER; FEMALE; GENE; GLUCOKINASE REGULATOR GENE; GLUCOSE TOLERANCE; HEPATIC FAT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; METABOLOMICS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TCF7L2 GENE; AGED; DIET THERAPY; FAT INTAKE; GENETIC PREDISPOSITION; GENETICS; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; LIVER; METABOLISM; MIDDLE AGED; THERAPEUTIC USE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; CHONDROITIN SULFATE PROTEOGLYCANS; DEUTERIUM; DIETARY FATS; DIETARY FIBER; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; LECTINS, C-TYPE; LIPASE; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MEMBRANE PROTEINS; METABOLOMICS; MIDDLE AGED; NERVE TISSUE PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; OLIVE OIL; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDIABETIC STATE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 85019065892     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-3722     Document Type: Article

References (37)

1. Gregg E, Imperatore G, Venkat Narayan K. Epidemiology of type 1and type 2 diabetes. In: Umpierrez G, ed. Therapy for Diabetes Mellitus and Related Disorders. 6th ed. Alexandria, VA: American Diabetes Association; 2014:77-96.
2. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R; Baltimore Longitudinal Study of Aging. The natural history of progressionfrom normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes. 2003;52(6):1475-1484.
3. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med. 1988;319(23):1500-1506.
4. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CDA, Nijpels G, Bouter LM, Heine RJ. Relation of impaired fastingand postload glucose with incident type 2 diabetes in a Dutchpopulation: The Hoorn Study. JAMA. 2001;285(16):2109-2113.
5. Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, Hardies J, Cusi K. Prevalence of prediabetes anddiabetes and metabolic profile of patients with nonalcoholic fattyliver disease (NAFLD). Diabetes Care. 2012;35(4):873-878.
6. Ryan MC, Abbasi F, Lamendola C, Carter S, Mc Laughlin TL. Serum alanine aminotransferase levels decrease further with carbohydratethan fat restriction in insulin-resistant adults. Diabetes Care. 2007;30(5):1075-1080.
7. Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liverdisease: An updated narrative review. World J Hepatol. 2015;7(3):575-582.
8. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testingthe effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121-129.
9. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. Aposition statement on NAFLD/NASH based on the EASL 2009special conference. J Hepatol. 2010;53(2):372-384.
10. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study ofLiver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and managementof non-alcoholic fatty liver disease: Practice guideline by theAmerican Association for the Study of Liver Diseases, American College of Gastroenterology, the American Gastroenterological Association. Am J Gastroenterol. 2012;107(6):811-826.
11. Barnard ND, Scialli AR, Turner-Mc Grievy G, Lanou AJ, Glass J. The effects of a low-fat, plant-based dietary intervention on bodyweight, metabolism, insulin sensitivity. Am J Med. 2005;118(9):991-997.
12. Yu H, Jia W, Guo Z. Reducing liver fat by low carbohydrate caloricrestriction targets hepatic glucose production in non-diabetic obeseadults with non-alcoholic fatty liver disease. J Clin Med. 2014;3(3):1050-1063.
13. Thoma C, Day CP, Trenell MI. Lifestyle interventions for thetreatment of non-alcoholic fatty liver disease in adults: A systematicreview. J Hepatol. 2012;56(1):255-266.
14. Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, Berglund J, Pulkki K, Basu S, Uusitupa M, Rudling M, Arner P, Cederholm T, Ahlström H, Risérus U. Effects of n-6 PUFAscompared with SFAs on liver fat, lipoproteins, inflammation inabdominal obesity: A randomized controlled trial. Am J Clin Nutr. 2012;95(5):1003-1012.
15. Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, O'Dea K, Desmond PV, Johnson NA, Wilson AM. The Mediterraneandiet improves hepatic steatosis and insulin sensitivity inindividuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59(1):138-143.
16. Westerbacka J, Lammi K, Häkkinen AM, Rissanen A, Salminen I, Aro A, Yki-J ärvinen H. Dietary fat content modifies liver fat inoverweight nondiabetic subjects. J Clin Endocrinol Metab. 2005;90(5):2804-2809.
17. van Herpen NA, Schrauwen-Hinderling VB, Schaart G, Mensink RP, Schrauwen P. Three weeks on a high-fat diet increases intrahepaticlipid accumulation and decreases metabolic flexibility in healthyoverweight men. J Clin Endocrinol Metab. 2011;96(4):E691-E695.
18. Utzschneider KM, Bayer-Carter JL, Arbuckle MD, Tidwell JM, Richards TL, Craft S. Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat inolder subjects. Br J Nutr. 2013;109(6):1096-1104.
19. Bozzetto L, Costabile G, Luongo D, Naviglio D, Cicala V, Piantadosi C, Patti L, Cipriano P, Annuzzi G, Rivellese AA. Reductionin liver fat by dietary MUFA in type 2 diabetes is helped by enhancedhepatic fat oxidation. Diabetologia. 2016;59(12):2697-2701.
20. Bozzetto L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A, Mazzarella R, Longobardo M, Mancini M, Vigorito C, Riccardi G, Rivellese AA. Liver fat is reduced by an isoenergeticMUFA diet in a controlled randomized study in type 2 diabeticpatients. Diabetes Care. 2012;35(7):1429-1435.
21. Fraser A, Abel R, Lawlor DA, Fraser D, Elhayany A. A modifiedMediterranean diet is associated with the greatest reduction inalanine aminotransferase levels in obese type 2 diabetes patients:results of a quasi-randomised controlled trial. Diabetologia. 2008;51(9):1616-1622.
22. Kaline K, Bornstein SR, Bergmann A, Hauner H, Schwarz PEH. The importance and effect of dietary fiber in diabetes preventionwith particular consideration of whole grain products. Horm Metab Res. 2007;39(9):687-693.
23. Vigue JT, Marsh HV, Jr, Pellett PL. Amino acid scores of dry beanproteins fractionated by deae cellulose. Agron J. 1978;70(6):1107-1108.
24. Kristal AR, Kolar AS, Fisher JL, Plascak JJ, Stumbo PJ, Weiss R, Paskett ED. Evaluation of web-based, self-administered, graphical foodfrequency questionnaire. J Acad Nutr Diet. 2014;114(4):613-621.
25. Hamilton G, Middleton MS, Bydder M, Yokoo T, Schwimmer JB, Kono Y, Patton HM, Lavine JE, Sirlin CB. Effect of PRESS andSTEAM sequences on magnetic resonance spectroscopic liver fatquantification. J Magn Reson Imaging. 2009;30(1):145-152.
26. Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition inNAFLD and NASH: Impact on severity of liver disease and responseto treatment. Curr Pharm Des. 2013;19(29):5219-5238.
27. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ, Nalls MA, Clark JM, Mitchell BD, Shuldiner AR, Butler JL, Tomas M, Hoffmann U, Hwang SJ, Massaro JM, O'Donnell CJ, Sahani DV, Salomaa V, Schadt EE, Schwartz SM, Siscovick DS, Voight BF, Carr JJ, Feitosa MF, Harris TB, Fox CS, Smith AV, Kao WH, Hirschhorn JN, Borecki IB; NASH CRN; GIANT Consortium;MAGIC Investigators; GOLD Consortium. Genome-wide associationanalysis identifies variants associated with nonalcoholic fattyliver disease that have distinct effects on metabolic traits. PLOSGenet. 2011;7(3):e1001324.
28. Persson XM, Blachnio-Zabielska AU, Jensen MD. Rapid measurementof plasma free fatty acid concentration and isotopic enrichmentusing LC/MS. J Lipid Res. 2010;51(9):2761-2765.
29. Basu R, Dalla Man C, Campioni M, Basu A, Nair KS, Jensen MD, Khosla S, Klee G, Toffolo G, Cobelli C, Rizza RA. Two years oftreatment with dehydroepiandrosterone does not improve insulinsecretion, insulin action, or postprandial glucose turnover in elderlymen or women [published correction appears in Diabetes 2007;56(5):1486]
30. Diabetes. 2007;56(3):753-766.
31. Man CD, Toffolo G, Basu R, Rizza RA, Cobelli C. Use of labeledoral minimal model to[measure hepatic insulin sensitivity. Am JPhysiol Endocrinol Metab. 2008;295(5):E1152-E1159.
32. Visentin R, Dalla Man C, Basu R, Basu A, Rizza RA, Cobelli C. Hepatic insulin sensitivity in healthy and prediabetic subjects:from a dual-to a single-tracer oral minimal model. Am J Physiol Endocrinol Metab. 2015;309(2):E161-E167.
33. Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, Valasek M, Lin G, Brenner D, Gamst A, Ehman R, Sirlin C. Magnetic resonance elastography predicts advanced fibrosis inpatients with nonalcoholic fatty liver disease: A prospective study. Hepatology. 2014;60(6):1920-1928.
34. Dinneen SF, Maldonado D III, Leibson CL, Klee GG, Li H, Melton LJ III, Rizza RA. Effects of changing diagnostic criteriaon the risk of developing diabetes. Diabetes Care. 1998;21(9):1408-1413.
35. Yki-Järvinen H. Nutritional modulation of non-alcoholic fatty liverdisease and insulin resistance. Nutrients. 2015;7(11):9127-9138.
36. Lee JJ, Lambert JE, Hovhannisyan Y, Ramos-Roman MA, Trombold JR, Wagner DA, Parks EJ. Palmitoleic acid is elevated infatty liver disease and reflects hepatic lipogenesis. Am J Clin Nutr. 2015;101(1):34-43.
37. Chong MF, Hodson L, Bickerton AS, Roberts R, Neville M, Karpe F, Frayn KN, Fielding BA. Parallel activation of de novo lipogenesisand stearoyl-Co A desaturase activity after 3 d of high-carbohydratefeeding. Am J Clin Nutr. 2008;87(4):817-823.